文献速递乳腺癌

Camizestrant(下一代口服SERD)对比氟维司群用于绝经后雌激素受体阳性、HER2阴性晚期乳腺癌(SERENA-2):多剂量、开放标签、随机、2期试验

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2024-01-01

SERENA-2研究纳入240例绝经后雌激素受体阳性、HER2阴性晚期乳腺癌患者,随机接受Camizestrant 75mg、150mg、300mg或氟维司群500mg治疗。主要终点为研究者评估的无进展生存期(PFS),Camizestrant 75mg和150mg组PFS均显著优于氟维司群组。安全性方面,Camizestrant组治疗相关不良事件发生率高于氟维司群组,但无治疗相关死亡。

要点

  • Camizestrant 75mg组中位PFS为7.2个月,氟维司群组为3.7个月,HR 0.59(90% CI 0.42-0.82;p=0.017)。
  • Camizestrant 150mg组中位PFS为7.7个月,氟维司群组为3.7个月,HR 0.64(90% CI 0.46-0.89;p=0.0090)。
  • Camizestrant 75mg组治疗相关不良事件发生率为53%,150mg组为67%,氟维司群组为18%。

核心结论

  • Camizestrant 75mg和150mg相比氟维司群在无进展生存期方面显示出显著获益。
  • 这些结果支持进一步开发Camizestrant用于治疗雌激素受体阳性、HER2阴性乳腺癌。

研究设计与样本

  • SERENA-2是一项开放标签、随机、2期试验,在亚洲、欧洲、中东和北美的74个研究中心进行。
  • 纳入年龄≥18岁、绝经后、组织学或细胞学确认的转移性或局部区域雌激素受体阳性、HER2阴性乳腺癌患者,ECOG或WHO体能状态评分为0或1,至少一线内分泌治疗后出现疾病复发或进展,晚期阶段既往内分泌治疗不超过一种。
  • 患者初始按1:1:1:1随机分配至口服Camizestrant每日一次75mg、150mg或300mg组(直至300mg组关闭),或氟维司群肌肉注射500mg(按说明书)组。
  • 随机化通过交互式网络系统管理,按既往CDK4/6抑制剂治疗和肝和/或肺转移分层。
  • 主要终点为研究者根据RECIST版本1.1评估的无进展生存期,在意向治疗所有随机分配患者(全分析集)中评估。

主要发现

  • 2020年5月11日至2021年8月10日期间,240例患者被随机分配至Camizestrant 75mg组(n=74)、150mg组(n=73)、300mg组(n=20)或氟维司群组(n=73),均纳入全分析集。
  • Camizestrant 75mg组中位随访时间为16.6个月(IQR 12.9-19.4),150mg组为16.3个月(12.9-18.3),氟维司群500mg组为14.7个月(12.7-20.1)。
  • Camizestrant 75mg组中位无进展生存期为7.2个月(90% CI 3.7-10.9),150mg组为7.7个月(5.5-12.9),氟维司群组为3.7个月(2.0-6.0)。
  • Camizestrant 75mg对比氟维司群的HR为0.59(90% CI 0.42-0.82;p=0.017),150mg对比氟维司群的HR为0.64(0.46-0.89;p=0.0090)。
  • 治疗相关不良事件发生率:Camizestrant 75mg组39/74(53%),150mg组49/73(67%),300mg组14/20(70%),氟维司群组13/73(18%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance to endocrine therapies in hormone receptor-positive breast cancer is challenging. We aimed to assess the next-generation oral selective oestrogen receptor degrader (SERD) and complete oestrogen receptor antagonist, camizestrant, versus the first-approved SERD, fulvestrant, in post-menopausal women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. METHODS: SERENA-2 is an open-label, randomised, phase 2 trial that is being conducted at 74 study centres across Asia, Europe, the Middle East, and North America. Female patients aged 18 years or older who were post-menopausal with histologically or cytologically confirmed metastastic or locoregional oestrogen receptor-positive, HER2-negative breast cancer, an Eastern Cooperative Oncology Group or WHO performance status of 0 or 1, and disease recurrence or progression on at least one line of endocrine therapy, and no more than one previous endocrine therapy in the advanced setting. Patients were initially randomly assigned (1:1:1:1) to receive oral camizestrant once daily at 75 mg, 150 mg, or 300 mg (until the 300 mg group was closed), or fulvestrant intramuscularly at 500 mg (per label). Randomisation was managed through an interactive web-based system and stratified by previous treatment with CDK4/6 inhibitors and presence of liver and/or lung metastases. The primary objective was to determine clinical efficacy of camizestrant versus fulvestrant at each dose level using the primary endpoint of investigator-assessed progression-free survival, per Response Evaluation Criteria in Solid Tumours (version 1.1), assessed by intention to treat in all randomly assigned patients (full analysis set). No formal statistical comparison for the efficacy analysis of the camizestrant 300 mg dose versus fulvestrant was to be performed. Safety analyses included all randomly assigned patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT04214288, and is ongoing. FINDINGS: Between May 11, 2020, and Aug 10, 2021, 240 patients were randomly assigned to receive camizestrant 75 mg (n=74), 150 mg (n=73), 300 mg (n=20), or fulvestrant (n=73), and were included in the full analysis set. All patients received at least one dose of study drug. Median follow-up was 16·6 months (IQR 12·9-19·4) for the camizestrant 75 mg group, 16·3 months (12·9-18·3) for the camizestrant 150 mg group, and 14·7 months (12·7-20·1) for the fulvestrant 500 mg group. Median progression-free survival was 7·2 months (90% CI 3·7-10·9) with camizestrant 75 mg, 7·7 months (5·5-12·9) with camizestrant 150 mg, and 3·7 months (2·0-6·0) with fulvestrant. The hazard ratio for camizestrant 75 mg versus fulvestrant was 0·59 (90% CI 0·42-0·82; p=0·017), and the hazard ratio for camizestrant 150 mg versus fulvestrant was 0·64 (0·46-0·89; p=0·0090). Treatment-related adverse events occurred in 39 (53%) of 74 patients in the camizestrant 75 mg group, 49 (67%) of 73 patients in the camizestrant 150 mg group, 14 (70%) of 20 patients in the camizestrant 300 mg group, and 13 (18%) of 73 patients in the fulvestrant group. No single grade 3 or worse treatment-emergent adverse event occurred in more than two (3%) patients in any group. Serious treatment-emergent adverse events occurred in six (8%) patients in the camizestrant 75 mg group, seven (10%) patients in the camizestrant 150 mg group, two (10%) patients in the camizestrant 300 mg group, and four (5%) patients in the fulvestrant group. No treatment-related deaths occurred. INTERPRETATION: Camizestrant at 75 and 150 mg showed a significant benefit in progression-free survival versus fulvestrant. These results support further development of camizestrant for the treatment of oestrogen receptor-positive, HER2-negative breast cancer. FUNDING: AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Oliveira M, Pominchuk D, Nowecki Z, et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024. PMID: 39481395. doi:10.1016/S1470-2045(24)00387-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。